IGSC 20% infusion
TAK-664-3002
Phase 3 mab completed
Quick answer
IGSC 20% infusion for Primary Immunodeficiency Disease is a Phase 3 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Primary Immunodeficiency Disease
- Phase
- Phase 3
- Modality
- mab
- Status
- completed